ZYME vs. RXRX, PTCT, OGN, RARE, ALVO, RNA, ADMA, ACLX, AKRO, and RYTM
Should you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Recursion Pharmaceuticals (RXRX), PTC Therapeutics (PTCT), Organon & Co. (OGN), Ultragenyx Pharmaceutical (RARE), Alvotech (ALVO), Avidity Biosciences (RNA), ADMA Biologics (ADMA), Arcellx (ACLX), Akero Therapeutics (AKRO), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry.
Zymeworks vs.
Zymeworks (NYSE:ZYME) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations, community ranking and risk.
In the previous week, Recursion Pharmaceuticals had 14 more articles in the media than Zymeworks. MarketBeat recorded 18 mentions for Recursion Pharmaceuticals and 4 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.78 beat Recursion Pharmaceuticals' score of 0.65 indicating that Zymeworks is being referred to more favorably in the media.
92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 1.9% of Zymeworks shares are owned by insiders. Comparatively, 15.8% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Zymeworks has a net margin of -182.75% compared to Recursion Pharmaceuticals' net margin of -579.52%. Zymeworks' return on equity of -23.00% beat Recursion Pharmaceuticals' return on equity.
Zymeworks received 262 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 67.75% of users gave Zymeworks an outperform vote while only 57.69% of users gave Recursion Pharmaceuticals an outperform vote.
Zymeworks has higher revenue and earnings than Recursion Pharmaceuticals. Zymeworks is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Zymeworks presently has a consensus price target of $19.17, indicating a potential upside of 33.19%. Recursion Pharmaceuticals has a consensus price target of $8.75, indicating a potential downside of 5.71%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts clearly believe Zymeworks is more favorable than Recursion Pharmaceuticals.
Zymeworks has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.
Summary
Zymeworks beats Recursion Pharmaceuticals on 15 of the 19 factors compared between the two stocks.
Get Zymeworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zymeworks Competitors List
Related Companies and Tools
This page (NYSE:ZYME) was last updated on 2/21/2025 by MarketBeat.com Staff
